Several initial preclinical studies in many cancer types, including melanoma, showed that CHK1 inhibitors act to potentiate chemotherapy, abrogating the G-M checkpoint, with a stronger activity in a p53 deficient tumor setting [12,78,110]. Here, CHEK1 is linked to neoplasm.